The Conversation (0)
Pharmabiz.com reports that Sigma Life Science, a subsididary of Sigma-Aldrich Corporation, has entered a non-exclusive license agreement with Horizon Discovery for use of Sigma’s CompoZr Zinc Finger Nuclease (ZFN) technology.
Pharmabiz.com reports that Sigma Life Science, a subsididary of Sigma-Aldrich Corporation, has entered a non-exclusive license agreement with Horizon Discovery for use of Sigma’s CompoZr Zinc Finger Nuclease (ZFN) technology. The agreement gives Horizon the commercial freedom to apply the technology alongside its proprietary rAAV technology in its gene-editing service and cell line product business units.
As quoted in the market news:
“Licensing CompoZr ZFN technology to Horizon is another step in making the most robust and flexible gene editing technology widely available to the entire research community,” said Paul Brooks, Ph.D., Global Market Segment Manager at Sigma-Aldrich. “We are pleased that Horizon will be using its expertize to apply both rAAV and CompoZr ZFN gene editing technologies side by side for the benefit of the research community.”
Click here for the full article on Pharmabiz.com